Reasons for this include that: (1) ER-positive metastatic breast cancer has thus far proven unresponsive to immune-based approaches [88, 89], and (2) early efforts to combine CDK4/6i and immuno-oncology therapy have been complicated by prohibitive toxicity [90, 91]. This evidence concerns the gene CDK4 and breast cancer.